ReportGem ReportGem

U.S. COMPANY FILING

Merck & Co., Inc. — Form 10-Q filed 2026-08-07

Filed: 2026-08-07Company: Merck & Co., Inc.Ticker: MRKExchange: NYSEForm: 10-QReport period: 2026-06-30SEC accession: 0000310158-26-000212Event: earningsMateriality: 85

Filing text preview

Merck's Q2 2026 sales rose 5% to $16.6B, but net loss of $5.58B in H1 due to $13.8B R&D charges from Cidara and Terns acquisitions. Keytruda sales grew, Welireg up 67%. Completed TARGAN acquisition, amended AstraZeneca collaboration, issued $6B notes.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-08-07Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20FORM 8-K2026-08-04 · 8-K1Q26 FORM 10-Q2026-05-04 · 10-QFORM 8-K2026-04-30 · 8-K10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 20252026-02-24 · 10-KFORM 8-K2026-02-03 · 8-K